Molecular Partners latest IPO failure, but others get through
Swiss biotech firm Molecular Partners became the latest victim of the recent bout of volatility in Europe’s markets, as it put its planned listing on hold on Tuesday. More deals could yet fail, bankers said.
The book had
not attracted enough investor demand to support an IPO, said a banker on the deal.
Already a subscriber? Login
Further Reading
-
SRI / Green Bonds
UK’s green Budget ‘underwhelming’ as gaps, contradictions appear
-
IPOs
Equity market cheers London listing review
-
ABBs/Block Trades
Shareholder sells Melexis shares to increase freefloat
-
Follow-Ons/Rights Issues
EDPR sells cheap to price €1.5bn 're-IPO' amid rising bond yields inflation fears